Two doctors on the front lines of the fight against COVID-19 return to discuss the current state of the global pandemic, from the promising vaccine news, to their cutting-edge antibody-treatment study recently published in the New England Journal of Medicine, to the brutal winter that awaits. Dr. Gregory Huhn, a Chicago-based infectious disease specialist, and Dr. Ajay Nirula, Eli Lilly’s VP of Immunology, also assess the impending changes under the Biden Administration, the need for attitudinal shifts regarding science and the realistic timeline for a return to packed stadiums, music festivals, Thanksgiving gatherings… and some semblance of normalcy.
Back in June, Dr. Gregory Huhn and Dr. Ajay Nirula--two highly accomplished medical experts on the front lines of the fight against COVID-19--joined us to discuss all things pandemic. They return with the latest on the worsening conditions throughout the country and the highly promising news on the vaccine and treatment fronts, providing answers to our questions about a potential ramp-up of testing and tracing, science skeptics, President-Elect Biden’s likely approach, President Trump’s post-treatment steroid high (and Dr. Huhn’s creative diagnosis) and how and when we can get back to normal. We also make Dr. Nirula pronounce the name of the antibody-therapy drug he and Dr. Huhn helped develop--as published in the New England Journal of Medicine--and suggest a few alternative monikers.